Prosigna Assay Kit

Enhance your treatment decisions with intrinsic subtypes

Put your patients’ prognostic information into action

  • Prosigna was developed based on the PAM50 gene signature, which measures the expression of 50 genes to classify tumors into 1 of 4 intrinsic subtypes1
  • Intrinsic subtypes provide valuable prognostic information to guide clinical decisions1,2
  • According to the St. Gallen guidelines, systemic therapy recommendations should follow intrinsic subtype classification2
PAM50 shows luminal A and luminal B subtypes have significantly different rates of DRFS

Accurately determine risk of recurrence with Prosigna

Risk of Recurrence (ROR) correlates with 10-year probability of distant recurrence1

The probability of distant recurrence within 10 years increases based on tumor size and nodal status. These data represent risk estimates derived from the clinical validation studies.1

Risk classification is also provided to allow interpretation of the ROR score by using cutoffs related to clinical outcome in tested patient populations.1 Three categorical risk groups (low, intermediate, and high) are defined based on predicted risk of distant recurrence at 10 years.2

10-year predicted breast cancer recurrence probability estimated within nodal status group
References: 1. Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013. 2. Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31(22):2783-2790.
Visitors: 16,584